KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EBT (2017 - 2025)

Amneal Pharmaceuticals has reported EBT over the past 9 years, most recently at $55.2 million for Q4 2025.

  • Quarterly results put EBT at $55.2 million for Q4 2025, up 460.57% from a year ago — trailing twelve months through Dec 2025 was $139.2 million (up 353.05% YoY), and the annual figure for FY2025 was $139.2 million, up 353.05%.
  • EBT for Q4 2025 was $55.2 million at Amneal Pharmaceuticals, up from -$5.2 million in the prior quarter.
  • Over the last five years, EBT for AMRX hit a ceiling of $55.2 million in Q4 2025 and a floor of -$232.7 million in Q2 2022.
  • Median EBT over the past 5 years was $68500.0 (2021), compared with a mean of -$8.6 million.
  • Peak annual rise in EBT hit 953.07% in 2023, while the deepest fall reached 990.28% in 2023.
  • Amneal Pharmaceuticals' EBT stood at -$16.3 million in 2021, then soared by 53.09% to -$7.7 million in 2022, then plummeted by 990.28% to -$83.5 million in 2023, then surged by 81.65% to -$15.3 million in 2024, then surged by 460.57% to $55.2 million in 2025.
  • The last three reported values for EBT were $55.2 million (Q4 2025), -$5.2 million (Q3 2025), and $51.7 million (Q2 2025) per Business Quant data.